Cambridge has always been a proving ground for ideas that don’t just enter the biotech race; they change the course. Predicta Biosciences is the latest to step into that lane, founded in 2023 by a crew of oncology heavyweights who don’t just write papers; they treat patients: Dr. Irene Ghobrial, Dr. Kenneth C. Anderson, Dr. Keith Flaherty, Dr. Gad Getz, and Dr. Romanos Sklavenitis-Pistofidis. This isn’t theory; it’s bedside reality wired into next-gen science.
Predicta Biosciences just closed an oversubscribed $23.4M Series A, led by Engine Ventures with Illumina Ventures, Lightchain Capital, Mass General Brigham Ventures, ACS BrightEdge, Binney Street Capital of Dana-Farber, and the Myeloma Solutions Fund stacking in. Add that to the $5.2M seed in 2024, and the tally sits at $28.6M. Enough capital to prove this isn’t hype; it’s execution.
And the leadership board just added another sharp piece: Brian McKernan, stepping in as CEO. McKernan’s track record is legit, a three-time biotech founder, most recently CEO of Fluent BioSciences before Illumina picked it up in 2024. Columbia MBA, former chair of the Analytical Life Sciences & Diagnostic Association, translation: a builder who knows how to scale complex science without drowning in it. He’s flanked by François Aguet (Head of Computational Biology), Doron Lipson (CTO), Valentina Nardi (Pathologist), and Thomas Mullen (CLIA Lab Director). This lineup isn’t a team; it’s a power move.
The company’s first product, GenoPredicta, launched April 2025. Already running at Dana-Farber, it’s used to assess prognosis, stratify risk, and flag therapy resistance in multiple myeloma. Whole genome sequencing across bone marrow and blood samples shows 100% concordance, outperforming traditional FISH by catching alterations others miss. It even predicts resistance to CAR-T & bispecific antibodies by detecting mutations in BCMA and GPRC5D. It meets International Myeloma Society and IMWG standards while sparing patients repeat invasive bone marrow pulls. That’s more than diagnostics; it’s relief built into precision.
Looking ahead, GenoPredicta MRD+ drops at the end of 2025 for minimal residual disease monitoring, with ImmunoPredicta set for 2026 to profile immune systems in MM patients. On deck: building a therapeutic pipeline sourced from their own genomic & immune profiling database. With the multiple myeloma diagnostics market growing from $3.5B in 2024 to $6.5B by 2032, and blood cancer diagnostics projected to hit $23.09B by 2033, the runway is massive.
This round isn’t just fuel; it’s validation. Predicta Biosciences is translating deep clinical science into scalable diagnostics with commercial muscle. Cambridge doesn’t need another promise; it needs delivery. And Predicta Biosciences looks primed to deliver.
